Migraine Treatment Names & Drug Classes Stocked in India

This piece covers each drug class actually used for migraine in India, how prophylaxis is chosen, where CGRP therapy fits today, and why hospital pharmacy stocking gaps in this specific area are unusually common.

What drug classes make up migraine treatment in India?

Indian migraine management uses four broad categories. NSAIDs and fixed-dose combination analgesics treat acute attacks and remain the most commonly prescribed group by far. Triptans (sumatriptan, rizatriptan, naratriptan) are migraine-specific abortive agents. Prophylactic agents include beta-blockers (propranolol), tricyclic antidepressants (amitriptyline), and flunarizine. Newer CGRP-pathway therapies, including the monoclonal antibody erenumab and the acute-treatment agent lasmiditan, have also entered Indian practice.

A 2025 study in Neurology India documenting real-world prescribing found migraine-specific drugs badly underused relative to guideline expectation, with most patients treated on NSAID-based regimens even for frequent, disabling attacks. That gap between guideline and practice is a genuine access and stocking problem, not just a prescribing-habit issue.

For a hospital pharmacy, the practical takeaway is that migraine names span a wider price and availability range than most single-condition drug lists. A cheap NSAID combination sits on almost every shelf. A triptan or a CGRP-class biologic often does not, and that gap is exactly where continuity of care breaks first.

How commonly are triptans actually prescribed for migraine in India?

Triptans remain a minority choice in Indian practice. The same real-world study found only around 5% of episodic migraine patients and 6% of chronic migraine patients were prescribed a migraine-specific drug such as a triptan or ergot derivative, even though these agents are the guideline-preferred acute option for moderate to severe attacks.

Cost, limited stocking at smaller pharmacies, and prescriber unfamiliarity all contribute to this gap. A hospital that does stock triptans reliably is, in practice, offering a level of guideline-concordant acute care that much of the outpatient market in India currently does not.

Sumatriptan, rizatriptan and naratriptan are the triptan-class migraine names most commonly available through Indian hospital and larger retail pharmacies, generally as oral tablets rather than the nasal or injectable formats sold in some other markets. A neurologist writing for one of these specific molecules expects the exact one to be available at refill, not a same-class substitute chosen at the counter.

What prophylactic drugs are used for frequent migraine, and are they used enough?

Beta-blockers, tricyclic antidepressants and flunarizine are the standard Indian prophylactic choices for patients with frequent or disabling attacks. The Neurology India data found that among patients with four or more episodic attacks a month, only about 25% were on adequate prophylaxis, while 39% received none at all and the remainder were on a suboptimal regimen.

This under-treatment pattern is well documented and matters operationally: a patient undertreated on prophylaxis returns more often for acute-attack care, which is itself a stocking-demand signal a hospital pharmacy should plan around rather than treat as random walk-in volume.

Propranolol and amitriptyline are inexpensive, widely stocked generics, so the prophylaxis gap in India is rarely a pure affordability problem. It more often reflects short consultation time, patients stopping a daily preventive drug once symptoms ease, and follow-up visits that lapse before a prescriber can review response and adjust the regimen.

Where does CGRP-pathway therapy fit in Indian migraine care today?

CGRP-targeted therapy is a newer addition to Indian practice. Erenumab, a monoclonal antibody against the CGRP receptor, is used for prophylaxis, and lasmiditan, a 5-HT1F receptor agonist structurally distinct from triptans, is used for acute treatment. Published clinical review notes growing evidence supporting anti-CGRP monoclonal antibodies as an earlier-line prophylactic option rather than a last resort after multiple failed agents.

Availability is uneven. A published review of Indian essential-medicine lists identified specific gaps in the inclusion of both triptans and newer CGRP-class drugs on several state essential drug lists, meaning formulary inclusion, not clinical evidence, is often the actual bottleneck to access.

CGRP-class migraine names also carry a materially higher price point than an older prophylactic, and cold-chain or specialty-pharmacy handling requirements for the injectable monoclonal antibody format add a stocking complexity that a standard outpatient counter is rarely set up to manage well.

What global burden data explains why migraine treatment access matters this much?

The World Health Organization ranks migraine third among all neurological conditions by disability-adjusted life years globally, and headache disorders overall affect an estimated 40% of the world's population. WHO also notes that only a minority of people with a headache disorder receive an appropriate diagnosis and treatment from a health provider, a gap that is at least as much a health-system and access issue as a clinical one.

That combination, high disease burden and low guideline-concordant treatment, is precisely why migraine names and their availability at the point of prescribing carry more operational weight than the condition's reputation as "just a headache" suggests. A neurological condition affecting two in five people worldwide, undertreated even where effective drugs exist, is a stocking priority, not an afterthought category in a hospital formulary.

Why does a hospital pharmacy's migraine stock list matter for continuity of care?

A patient stabilised on a specific triptan or started on erenumab prophylaxis during a neurology consult needs that same drug reliably available at refill, not a substitution decided by whichever chemist happens to be nearest. Triptan and CGRP-class products are not universally stocked outside major urban pharmacies, and a hospital that can't fill its own neurologist's prescription sends that patient, and that revenue, to an outside counter.

Our prescription leakage guide covers what that walk-out costs a hospital across a full patient relationship, and our managed hospital pharmacy services piece covers how in-house stocking of lower-volume, higher-value neurology drugs like these is exactly the kind of gap a managed pharmacy model is built to close. A neurology outpatient department that repeatedly sends its own migraine names list to an outside chemist is, in effect, subsidising a competitor's pharmacy with its own consultation volume.

Sources

1. 1The Treatment Profile of Migraine in India: A Glimpse of Real-World Practice — Neurology India, 2025
2. 2Migraine and other headache disorders — World Health Organization
3. 3It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine — National Institutes of Health, National Library of Medicine
4. 4Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
5. 5National List of Essential Medicines (NLEM) 2022 — CDSCO / Ministry of Health and Family Welfare

This article is for informational purposes and is for hospital and clinical administrators, not patients seeking self-treatment advice. It is not a substitute for professional medical advice; drug names, classes and availability cited here change over time and should be verified against current primary sources. Consult a qualified physician before making any treatment decision.